Albireo Pharma

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The average of price targets set by Wall Street analysts indicates a potential upside of 183.9% in Albireo Pharma (ALBO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict an 184% Upside in Albireo Pharma (ALBO): Here's What You Should Know

The stock price of Albireo Pharma Inc (NASDAQ: ALBO) increased by 1.55% in the most recent trading session. This is why it happened.

Albireo Pharma Stock (ALBO): Why The Price Increased

– Bylvay net sales guidance revised to $6-7M vs. expectations of $3-4M

Albireo Increases 2021 Bylvay™ (odevixibat) Sales Guidance

ACADIA Pharma

Rocket Pharma

Theseus Pharmaceuticals

Xeris Biopharma Holdings

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in programs and the reemergence of variant strains.

5 Beaten Down Biotech Stocks That Could Bounce Big In 2022

– First oral, systemic ASBT inhibitor was safe and well tolerated

Albireo Announces Positive Topline Data from Phase 1 Study of A3907

– Data show significant correlations in serum bile acid reductions and long-term improvements in pruritus and sleep

Albireo Presenting New Bylvay™ (odevixibat) Data at NASPGHAN 2021

BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the upcoming departure of Pat Horn, M.D., Ph.D., Chief Medical Officer, who will be leaving at the end of the year after almost three and a half years with the Company. Jan Mattsson, Ph.D., Chief Scientific Officer and co-founder of Albireo, will be taking over as the interim head of R&D, leading research and development of early and late-stage assets and programs. As one of the co-founders of the Company with deep experience in drug development and approvals, Dr. Mattsson is primed to lead the R&D organization with his institutional knowledge, vision for the pipeline and products, and ability to deliver against corporate objectives.

Albireo Announces Changes to R&D Organization

– New chief business officer to oversee Company's corporate and business development strategy – – New chief business officer to oversee Company's corporate and business development strategy –

Albireo Expands Leadership with Constantine Chinoporos as Chief Business Officer

Albireo developed Odevixibat - a product as a pipeline - as a life-saving therapy for multiple ultra-rare pediatric liver disease indications.

Albireo: Reasons For A Successful Transformation Into A Commercial Company

Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q3 2021 Results - Earnings Call Transcript

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -333.33% and -83.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Albireo Pharma (ALBO) Reports Q3 Loss, Lags Revenue Estimates

– Bylvay™  (odevixibat) approved in the U.S. and Europe, partial Q3 '21 revenue of $1.1 million –

Albireo Reports Q3 Financial Results and Business Update

Albireo Pharma (ALBO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Albireo Pharma (ALBO) to Report Q3 Results: Wall Street Expects Earnings Growth

— Conference call and webcast to be held at 10:00 a.m. ET — — Conference call and webcast to be held at 10:00 a.m. ET —

Albireo to Report Third Quarter 2021 Financial Results on November 4

– Seven abstracts accepted highlighting data in pediatric cholestatic and viral liver diseases –

Albireo to Showcase New Data at AASLD The Liver Meeting® 2021

– Agreement to accelerate commercialization of Bylvay™ (odevixibat) in Japan, a significant market for PFIC, Alagille syndrome and biliary atresia –

Albireo Announces Exclusive Licensing Agreement with Jadeite Medicines for Bylvay™ (odevixibat) in Japan

BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network (PFIC Network) in recognition of PFIC Awareness Day 2021, a global effort to support patients and families affected by progressive familial intrahepatic cholestasis (PFIC). Established in 2019, PFIC Awareness Day aims to highlight the impact of this disease on patients and families, and to call for new levels of support, including research, advocacy, education and opportunities to connect and share information.

Albireo Recognizes PFIC Awareness Day 2021

– Listed on the German national price list and all pharmacy software programs –

Albireo Announces Bylvay® (odevixibat) Now Available in Germany

– Bylvay now approved in U.S., EU and UK as first drug treatment for patients with PFIC –

Albireo Receives UK MHRA Approval of Bylvay® (odevixibat)

Albireo Pharma Inc (NASDAQ: ALBO) has agreed to sell its Priority Review Voucher (PRV) for $105 million.  The FDA granted the PRV for Bylvay to treat pruritus in all types of progressive familial intrahepatic cholestasis (PFIC).

Albireo Pharma Sells Bylvay-Associated PRV For $105M

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, Simon Harford, Chief Financial Officer and other members of the Company's management team will be presenting at the following investor conferences:

Albireo to Present at Upcoming Investor Conferences

– Bylvay is approved in the U.S. and EU as only once-daily drug indicated for patients with PFIC –

Albireo and Genpharm Announce Agreement to Commercialize Bylvay™ (odevixibat) in Saudi Arabia and the Gulf Region

Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q2 2021 Results - Earnings Call Transcript

ALBIREO PHARMA (ALBO) delivered earnings and revenue surprises of 1.04% and -6.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ALBIREO PHARMA (ALBO) Reports Q2 Loss, Misses Revenue Estimates

– Bylvay TM (odevixibat) approved in U.S. & EU as o nly once-daily drug indicated for patients with PFIC –

News for Albireo Pharma Stock (ALBO)